- A recent clinical trial involving metastatic (Stage 4) breast cancer patients taking the experimental drug trastuzumab deruxtecan (sold as Enhertu) found that it stopped tumors from growing for 10 months and patients survived for 23.9 months, an “unheard-of” 5 and 7 additional months relative to standard chemotherapy.
- While existing treatments are highly effective against mutant HER2 proteins, HER2-positive cases account for only 15-20% of breast cancer patients.
- Enhertu’s uniqueness derives from seeping through the cancerous cell’s membrane and killing nearby cancer cells.
